A case of cytomegalovirus esophagitis during immunotherapy for esophageal cancer and a review of the literature
食管癌免疫治疗过程中发生巨细胞病毒食管炎1例并回顾文献

参考文献 References

[1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.

[2] Hoversten P, Kamboj AK, Wu TT, Katzka DA. Risk Factors, Endoscopic Features, and Clinical Outcomes of Cytomegalovirus Esophagitis Based on a 10-year Analysis at a Single Center. Clin Gastroenterol Hepatol. 2020; 18(3):736-8.

[3] Aizawa R, Matsumoto S, Uneno Y, Nishikawa Y, Ozaki Y, Mori Y, et al. Severe esophagitis associated with cytomegalovirus during concurrent chemoradiotherapy for esophageal cancer. Jpn J Clin Oncol. 2017;47(9):885-8.

[4] Umemoto K, Kojima Y, Nagata N, Yokoi C, Sakurai T, Kobayakawa M, et al. Cytomegalovirus esophagitis developing during chemoradiotherapy for esophageal cancer: two case reports. J Med Case Rep. 2016;10(1):259.

[5] Murata T. Human Herpesvirus and the Immune Checkpoint PD-1/PD-L1 Pathway: Disorders and Strategies for Survival. Microorganisms. 2021;9(4).

[6] Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-73.

[7] Ohnuma H, Sato Y, Takayama T, Takimoto R, Abe T, Hagiwara S, et al. Esophageal cancer complicated by cytomegalovirus esophagitis during chemoradiotherapy: case report. Gastrointest Endosc. 2003;57(4):622-6.

[8] Sezgin E, An P, Winkler CA. Host Genetics of Cytomegalovirus Pathogenesis. Front Genet. 2019;10:616.

[9] Herbein G. Tumors and Cytomegalovirus: An Intimate Interplay. Viruses. 2022;14(4).

[10] Gueguen J, Bailly E, Machet L, Miquelestorena-Standley E, Stefic K, Gatault P, et al. CMV disease and colitis in a kidney transplanted patient under pembrolizumab. Eur J Cancer. 2019;109:172-4.

[11] Murakami D, Harada H, Yamato M, Amano Y. Cytomegalovirus-associated esophagitis on early esophageal cancer in immunocompetent host: a case report. Gut Pathog. 2021;13(1):24.

[12] Hu L, Wen Z, Chen J, Chen Y, Jin L, Shi H, et al. The cytomegalovirus UL146 gene product vCXCL1 promotes the resistance of hepatic cells to CD8(+) T cells through up-regulation of PD-L1. Biochem Biophys Res Commun. 2020;532(3):393-9.

[13] Benedict CA, Loewendorf A, Garcia Z, Blazar BR, Janssen EM. Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. J Immunol. 2008;180(7):4836-47.

[14] Parry HM, Dowell AC, Zuo J, Verma K, Kinsella FAM, Begum J, et al. PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity. PLoS Pathog. 2021;17(3):e1009349.

[15] Erkes DA, Smith CJ, Wilski NA, Caldeira-Dantas S, Mohgbeli T, Snyder CM. Virus-Specific CD8(+) T Cells Infiltrate Melanoma Lesions and Retain Function Independently of PD-1 Expression. J Immunol. 2017; 198(7): 2979-88.